Exclusive: ACR Convergence 2024| Focus Rheums

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Insights into Methotrexate Toxicity in Elderly Patients with Rheumatic Disease

  |  Issue: February 2023  |  

Michele B. Kaufman, PharmD, BCGP, is a freelance medical writer based in New York City and a pharmacist at New York Presbyterian Lower Manhattan Hospital.

References

  1. Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Rheumatol. 2021 Jul;73(7):1108–1123.
  2. Kumar C, Herrmann K, Aringer M, et al. Severe low-dose methotrexate toxicity in elderly patients with inflammatory rheumatic diseases [abstract 0929]. Arthritis Rheumatol. 2022;74(suppl 9).
  3. Pivovarov K, Zipursky JS. Five things to know about low-dose methotrexate toxicity. CMAJ. 2019 April 15;19:E423.

Related Articles

    Difficult Gout

    “Grandpapa’s Torments” was the Rodnan Commemorative Gout Print featured at the 2005 ACR/ARHP Annual Scientific Meeting.

    Lost and found

    The History of ACE Inhibitors in Scleroderma Renal Crisis

    Scleroderma renal crisis is a true medical emergency in rheumatology, one that requires prompt diagnosis and treatment. Here, we review the historic introduction of the angiotensin-converting enzyme inhibitors in this context, and highlight management and key questions moving forward. Background Awareness of renal disease in scleroderma dates back many years. The revered physician William Osler…